Thompson Davis & CO. Inc. Acquires New Holdings in RxSight, Inc. (NASDAQ:RXST)

Thompson Davis & CO. Inc. acquired a new stake in shares of RxSight, Inc. (NASDAQ:RXST) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 5,250 shares of the company’s stock, valued at approximately $212,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. RiverPark Advisors LLC grew its holdings in RxSight by 70.0% during the fourth quarter. RiverPark Advisors LLC now owns 668 shares of the company’s stock valued at $27,000 after purchasing an additional 275 shares during the last quarter. BluePath Capital Management LLC acquired a new position in RxSight during the third quarter valued at approximately $32,000. Clarus Group Inc. acquired a new position in RxSight during the fourth quarter valued at approximately $202,000. Penn Mutual Asset Management LLC acquired a new position in RxSight during the third quarter valued at approximately $230,000. Finally, Arizona State Retirement System acquired a new stake in shares of RxSight in the fourth quarter worth $261,000. Institutional investors own 78.78% of the company’s stock.

RxSight Stock Down 2.1 %

RXST traded down $1.13 during trading on Tuesday, reaching $52.13. 305,555 shares of the company’s stock were exchanged, compared to its average volume of 424,615. RxSight, Inc. has a fifty-two week low of $17.59 and a fifty-two week high of $58.21. The business has a 50 day moving average price of $52.48 and a 200 day moving average price of $42.34. The company has a market capitalization of $1.94 billion, a P/E ratio of -36.45 and a beta of 1.22.

RxSight (NASDAQ:RXST) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.10. The firm had revenue of $28.58 million for the quarter, compared to the consensus estimate of $28.60 million. RxSight had a negative net margin of 54.57% and a negative return on equity of 31.16%. As a group, research analysts forecast that RxSight, Inc. will post -0.94 EPS for the current year.

Insider Buying and Selling at RxSight

In other RxSight news, CFO Shelley B. Thunen sold 9,125 shares of RxSight stock in a transaction on Monday, February 5th. The stock was sold at an average price of $47.02, for a total transaction of $429,057.50. Following the completion of the transaction, the chief financial officer now directly owns 13,691 shares of the company’s stock, valued at $643,750.82. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, Director William J. Phd Link sold 28,250 shares of RxSight stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $49.67, for a total value of $1,403,177.50. Following the completion of the transaction, the director now directly owns 24,248 shares of the company’s stock, valued at $1,204,398.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Shelley B. Thunen sold 9,125 shares of RxSight stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $47.02, for a total value of $429,057.50. Following the completion of the transaction, the chief financial officer now directly owns 13,691 shares of the company’s stock, valued at $643,750.82. The disclosure for this sale can be found here. Over the last three months, insiders sold 94,869 shares of company stock valued at $4,771,244. 21.13% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on RXST shares. Needham & Company LLC restated a “buy” rating and issued a $64.00 price objective on shares of RxSight in a research note on Thursday, April 11th. Oppenheimer raised their price objective on shares of RxSight from $54.00 to $61.00 and gave the stock an “outperform” rating in a research note on Thursday, February 29th. JPMorgan Chase & Co. raised their price objective on shares of RxSight from $40.00 to $62.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. Finally, Stifel Nicolaus raised their price objective on shares of RxSight from $54.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $49.63.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.